
Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:NVO), trimmed its 2025 financial outlook.
The cut marks the second time this year Novo Nordisk has lowered its guidance.

Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:NVO), trimmed its 2025 financial outlook.
The cut marks the second time this year Novo Nordisk has lowered its guidance.